Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea flag South Korea · Delayed Price · Currency is KRW
114,700
-7,100 (-5.83%)
Jan 19, 2026, 3:30 PM KST
446.19%
Market Cap2.44T
Revenue (ttm)25.48M
Net Income (ttm)-36.88B
Shares Out21.23M
EPS (ttm)-2,048.17
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume402,033
Average Volume464,746
Open120,900
Previous Close121,800
Day's Range114,100 - 122,500
52-Week Range15,950 - 146,600
Betan/a
RSI53.89
Earnings DateMar 20, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 475830
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.